Stimulation of the beta-2 adrenergic receptor for activating human brown adipose tissue

A0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•- Diabetes mellitus (determined on basis of fasting glucose levels defined by ADA criteria)
•- Any other active endocrine disease (thyroid disease, any signs of Cushing’s syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia)
•- Any cardiac disease (i.e. ischemic cardiac disease, arrhythmias, severe heart failure)
•- A first-degree family member with sudden cardiac death
•- Any chronic renal or hepatic disease
•- Use of beta-adrenergic receptor agonists (for e.g. asthma)
•- Use of medication known to influence glucose and/or lipid metabolism or brown fat activity (e.g. beta-blockers, antidepressants, corticosteroids)
•- Use of medication shown to increase risk on hypokalemia after salbutamol administration (e.g. xanthine derivatives, steroids and diuretics)
•- Any other contra-indications for the use of salbutamol or propranolol
•- Abuse of alcohol or other substances
•- Participation in an intensive weight-loss program or vigorous exercise program during the last year before the start of the study
•- Current participation in another research projects that may influence the current research project
•- Participation in another research with exposure to radiation burden within a year before the start of the current study
•- Clinically relevant abnormalities in clinical chemistry or electrocardiogram (ECG) at screening (to be judged by the study physician)

发起方